Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy
Anthony R. Mato,
William G. Wierda,
Matthew S. Davids,
Bruce D. Cheson,
Steven E. Coutre,
Michael Choi,
Richard R. Furman,
Leonard Heffner,
Paul M. Barr,
Herbert Eradat,
Sharanya M. Ford,
Lang Zhou,
Maria Verdugo,
Rod A. Humerickhouse,
Jalaja Potluri,
John C. Byrd
Affiliations
Anthony R. Mato
CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
William G. Wierda
University of Texas MD Anderson Cancer Center, Houston, TX
Matthew S. Davids
Dana-Farber Cancer Institute, Boston, MA
Bruce D. Cheson
Georgetown University Hospital, Washington, DC
Steven E. Coutre
Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA
Michael Choi
UCSD Moores Cancer Center, San Diego, CA
Richard R. Furman
Weill Cornell Medicine, New York, NY
Leonard Heffner
Emory University School of Medicine, Atlanta, GA
Paul M. Barr
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Herbert Eradat
University of California Los Angeles, Los Angeles, CA
The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter’s transformation versus chronic lymphocytic leukemia (CLL) progression after ibrutinib and/or idelalisib was assessed in a post hoc analysis of a phase II study of venetoclax. Patients underwent PET-CT at screening and were not enrolled/treated if Richter’s transformation was confirmed pathologically. Of 167 patients screened, 57 met criteria for biopsy after PET-CT. Of 35 patients who underwent biopsy, eight had Richter’s transformation, two had another malignancy, and 25 had CLL. A PET-CT maximum standardized uptake value (SUVmax) ≥10 had 71% sensitivity and 50% specificity for detecting Richter’s transformation [Odds Ratio (OR): 2.5, 95%CI: 0.4-15; P=0.318]. Response rate to venetoclax was similar for screening SUVmax
